| Literature DB >> 25490429 |
Samir Aquino Carvalho1, Marcel Kaiser2, Reto Brun3, Edson Ferreira da Silva4, Carlos Alberto Manssour Fraga5.
Abstract
A series of 14 (E)-cinnamic N-acylhydrazone derivatives, designed through molecular hybridization between the (E)-1-(benzo[d][1,3]dioxol-5-yl)-3-(4-bromophenyl)prop-2-en-1-one and (E)-3-hydroxy-N'-((2-hydroxynaphthalen-1-yl)methylene)-7-methoxy-2-naphthohydrazide, were tested for in vitro antiparasitic activity upon axenic amastigote forms of Leishmania donovani and bloodstream forms of Trypamosoma brucei rhodesiense. The derivative (2E)-3-(4-hydroxy-3-methoxy-5-nitrophenyl)-N'-[(1E)-phenylmethylene]acrylohydrazide showed moderate antileishmanial activity (IC50 = 6.27 µM) when compared to miltefosine, the reference drug (IC50 = 0.348 µM). However, the elected compound showed an excellent selectivity index; in one case it was not cytotoxic against mammalian L-6 cells. The most active antitrypanosomal compound, the derivative (E)-N'-(3,4-dihydroxybenzylidene)cinnamohydrazide (IC50 = 1.93 µM), was cytotoxic against mammalian L-6 cells.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25490429 PMCID: PMC6271834 DOI: 10.3390/molecules191220374
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Design concept of cinnamic N-acylhydrazone derivatives (3–16).
In vitro trypanocidal, leishmanicidal and cytotoxic activities of the cinnamic N-acylhydrazone derivatives (3–16).
| Cpd. | R1 | R2 | R3 | R4 |
| Cytot. L-6 Cells c | SI d | SI e | |
|---|---|---|---|---|---|---|---|---|---|
| IC50 f (μM) | |||||||||
| 3 | H | OMe | OH | NO2 | 6.27 | 45.6 | >264 | >42 | >5.8 |
| 4 | H | OMe | OH | H | 21.7 | 40.8 | 95.4 | 4.4 | 2.3 |
| 5 | H | OH | OH | H | 11.7 | 1.93 | 14.0 | 1.2 | 7.3 |
| 6 | H | O-CH2-O | H | 12.5 | 89.5 | 4.3 | 0.3 | 0.05 | |
| 7 | H | OMe | OMe | OMe | 3.50 | 49.3 | 120 | 34.3 | 2.4 |
| 8 | H | H | F | H | 24.3 | 284 | >335 | >13.8 | >1.2 |
| 9 | H | H | NO2 | H | 10.6 | >300 | 255 | 24.1 | - |
| 10 | H | H | OMe | H | 13.8 | 111 | >321 | 23.3 | 2.9 |
| 11 | H | H | Cl | H | 10.8 | 121 | 65.5 | 6.0 | 0.5 |
| 12 | H | H | H | H | 43.1 | >300 | 157 | 3.6 | - |
| 13 | H | H | OH | H | 36.7 | 82.5 | 40.4 | 1.1 | 0.5 |
| 14 | H | OMe | OMe | H | 31.2 | 67.6 | >290 | >9.3 | >4.3 |
| 15 | OH | H | H | H | 3.61 | 6.72 | 14.9 | 4.1 | 2.2 |
| 16 | H | OH | OMe | H | 33.3 | 80.1 | 48.1 | 1.4 | 0.6 |
| MTS | - | - | - | - | 0.348 | - | ND | - | - |
| MLSP | - | - | - | - | - | 0.003 | ND | - | - |
| PPT | - | - | - | - | - | - | 0.006 | - | - |
a Leishmania donovani (MHOM/ET/67/L82) axenic amastigotes [18]; b Trypanosoma brucei rhodesiense (STIB900) [19,20]; c Cytotoxicity to L-6 rat myoblast cells [20]; d Selectivity Index for leishmanicidal activity; e Selectivity Index for trypanocyde activity; f IC50 values are means of two determinations. ND = Value not determined. Reference drugs: MTS (Miltefosine); MLSP (Melarsoprol); PPT (Podophyllotoxin).